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Original Article

Pacritinib to inhibit JAK/STAT signaling in refractory metastatic
colon and rectal cancer
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Background: Treatment options for patients with refractory colorectal cancer are limited and typically
provide a chance of only modest benefit. The goal of this study was to evaluate the benefit of inhibiting
the JAK/STAT inflammatory pathway with single agent pacritinib in patients with metastatic refractory
colorectal adenocarcinoma.
Methods: A single arm institutional trial was initiated and enrolled patients with metastatic colorectal
cancer refractory to at least two standard lines of treatment. Pacritinib 400 mg daily was administered orally
continuously in 28 day cycles.
Results: The trial was discontinued prior to reaching the planned accrual due to an FDA hold on pacritinib
and a lack of treatment benefit. Eleven patients were enrolled and seven were evaluated for response. Median
baseline C-reactive protein level was 12.1 (2.1–147) mg/L. One patient had stable disease at eight weeks by
RECIST criteria and six progressed. There were no grade 4 or 5 adverse events while patients were on study.
The grade 2 and lower AE events experienced were consistent with prior pacritinib trials.
Conclusions: In seven evaluable patients there were no objective responses. The trial was discontinued
prior to completing planned accrual based on a low likelihood that the progression free survival goal of
4 months would be met.
Keywords: Pacritinib; refractory; colorectal cancer
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Introduction
Treatment options for patients with metastatic colon
and rectal cancer (CRC) that have progressed following
standard first and second lines of treatment are limited.
The approvals of regorafenib and TAS-102 filled a void;
however, results are disappointing for most patients (1,2).
Patients with microsatellite unstable tumors may benefit
from immunotherapy, however this represents a minority

© Journal of Gastrointestinal Oncology. All rights reserved.

of cases (3). Novel approaches are needed for patients with
refractory CRC (4).
Pre-clinical studies have demonstrated that cytokine
mediated inflammation plays a role in carcinogenesis
and prognosis in CRC (5). Interleukin-6 (IL-6) is an
inflammatory cytokine that binds to receptors that mediate
signaling by the JAK/STAT pathway. Phosphorylated
STAT3 is a transcription promoter of genes associated with
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cell survival, proliferation, angiogenesis, metastasis, cell
adhesion, and inflammation (6). Inhibiting this pathway
in both CRC cell lines and mouse CRC xenograft models
resulted in apoptosis and tumor responses (7).
Pacritinib is an orally administered multi-kinase
inhibitor with potent JAK and FLT3 inhibition. It has been
extensively evaluated in early phase trials in hematologic
m al ig n a n c ie s in c lu d i ng myel o fi b ro s i s , AML, an d
myeloproliferative neoplasms and shown to have a favorable
safety profile (8).
This phase II single arm, single institutional trial
sought to examine the effect of JAK/STAT inhibition with
pacritinib in patients with refractory colorectal cancers.
Methods

treating physician.
Correlative studies
Planned correlative studies included measurement of
erythrocyte sedimentation rate and C-reactive protein.
Serum IL-6 and interleukin-8 (IL-8) levels were also
measured at baseline and monthly on treatment.
Statistical considerations
We proposed a meaningful primary outcome favoring
continued development of pacritinib in refractory CRC was
a median PFS of 4 months. The planned sample size of 38
patients would have given the study ≥0.90 power to identify
an increase in median PFS from 1.7 to 4.0 months.

Eligibility criteria
Eligible patients had metastatic CRC refractory or
intolerant to at least two lines of chemotherapy and
evaluable or measurable disease by RECIST version 1.1,
and Eastern Cooperative Oncology Group performance
status of 0 or 1. Patients also had to be ≥18 years old with
adequate bone marrow, hepatic and renal function as well as
life expectancy of at least 3 months. Key exclusion criteria
included prior therapy with JAK or FLT3 inhibitors,
chemotherapy or targeted agent within 2 weeks of initiating
study drug, known brain metastasis, or uncontrolled
intercurrent illness. The protocol (ClinicalTrials.gov
identifier: NCT02277093) was approved by the institutional
review board of Washington University (IRB00009237)
and written informed consent was obtained for all patients
before performing study-related procedures.
Drug administration and study design
Pacritinib was administered orally continuously on a
28-day cycle at a dose of 200 mg twice daily. This dose
was determined based on published phase one studies
of pacritinib in patients with myeloid malignancies and
myeloproliferative neoplasms (9). Patients underwent a
baseline history and physical examination, ECG including
QTc measurement, CT chest/abdomen/pelvis within 4
weeks, and CBC, CMP, and magnesium measurement.
While on treatment patients were monitored with weekly
blood work and every other week office visits and ECG
with QTc measurement. Response assessment was by CT
scans every two cycles or sooner if deemed necessary by the
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Results
Patient population
Eleven patients with refractory metastatic colon or rectal
cancer were enrolled between September 2015 and February
2016. Patient characteristics are presented in Table 1.
Median age was 63 years. All patients had been treated with
FOLFOX and FOLFIRI. The three RAS wildtype patients
had received panitumumab and nine patients had received
bevacizumab. Five patients had participated in other clinical
trials. The baseline median CRP level was 12.1 mg/L with a
range of 2.1 to 147 mg/L.
Adverse events
All patients experienced at least grade 1 or 2 adverse events.
The most common being nausea (5 patients, 50%) followed
by abdominal cramping and constipation. Five patients
experienced a total of 14 unique grade 3 adverse events.
There were no grade 4 or 5 events on study (Table 2).
Correlative studies
CRP and interleukin concentrations at baseline and
after the first cycle were available for 7 and 9 patients
respectively. Interleukin 6 and 8 plasma levels were
measured by Luminex high sensitivity multiplex assay. The
patient with stable disease by RECIST at 2 months had
the lowest baseline CRP of 2.1 mg/L. The patient with
the highest CRP on study, 147 mg/L had a large burden of
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Table 1 Characteristics of the eleven patients
Characteristic

Table 2 Adverse events in 10 evaluable patients
Value

Age, year
Median [range]
Female, no. [%]

987

63 [43–80]
7 [64]

Primary site, no. [%]

No. of events [%]

Event

Grade 1/2

Grade 3

45 [100]

14 [50]

Nausea

5 [50]

1 [10]

Abdominal discomfort

4 [40]

0

Any adverse event

Right colon

7 [64]

Constipation

3 [30]

0

Left colon

2 [18]

Fatigue

3 [30]

0

Rectum

2 [18]

Mucositis

2 [20]

0

8 [73]

Peripheral edema

2 [20]

0

Diarrhea

1 [10]

0

Vomiting

1 [10]

0

Rash

1 [10]

0

Thrombocytopenia

0

1 [10]

Alkaline phosphatase increase

0

1 [10]

Serum bilirubin increase

0

1 [10]

RAS mutation, no. [%]
Baseline CRP, mg/L
Median [range]
Received adjuvant therapy, no. [%]

12.1 [2.1–147]
3 [27]

Prior lines of therapy for metastatic disease, no.
Median [range]

4 [2–6]

Prior treatment, no. [%]
FOLFOX/XELOX

11 [100]

Pleural effusion

0

1 [10]

FOLRIRI

11 [100]

Anemia

0

1 [10]

Bevacizumab

9 [82]

Regorafenib

6 [55]

TAS-102

5 [45]

Clinical trial

5 [45]

Panitumumab

3 [27]

Xeloda

2 [18]

liver metastasis and an elevated total bilirubin not related
to pacritinib. IL-6 and IL-8 levels increased in all patients
after 1 month of treatment (Figure 1).
Antitumor efficacy
Seven patients were evaluable for response while four
patients discontinued due to an FDA hold on pacritinib
prior to first radiographic imaging. Of the 7 evaluable
patients, 6 had disease progression while 1 had stable disease
by RECIST criteria. No patient continued pacritinib for
longer than 8 weeks.
Discussion
This study sought to demonstrate that inhibition of the
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There were no grade 4/5 events reported. One patient was not
included due to short duration on treatment.

JAK/STAT cytokine signaling pathway would lead to
clinically meaningful responses in patients with refractory
CRC. After eleven patients accrued and were initiated
on treatment the Food and Drug Administration of the
United States issued an order holding administration of
pacritinib and halting clinical trial enrollment. This was
based on emerging adverse safety data from the PERSIST-1
trial in patients with myelofibrosis treated with pacritinib.
During the clinical hold we determined that re-opening the
study with additional safety parameters was not in the best
interest of our patients given the lack of observed response
to the investigational agent and uncertainty as to the safety
of pacritinib.
While we cannot evaluate the effect of pacritinib on
our primary and secondary endpoints, several observations
were made. The drug was only discontinued in one patient
due to intolerance. There were no grade 4/5 events and no
cardiovascular events were observed. The safety evaluation
is limited by the short duration of treatment. Correlative
analysis of inflammatory markers demonstrated an increase
over the course of one month on treatment. Our opinion is
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Figure 1 Study participant serum concentrations for CRP and IL-6. Normalized serum concentrations of (A) CRP and (B) IL-6 at baseline
and after one cycle of treatment with pacritinib. Each line represents an individual patient who had both the blood test at baseline and at the
beginning of cycle 2. CRP, C-reactive protein.

that this finding is most likely related to progressive disease
but the possibility of an interaction with pacritinib should
be explored further. We were unable to find published
reports of CRP, IL-6 or IL-8 measurement in patients
treated with pacritinib or other JAK inhibitors.
The hypothesis that patients with high CRP levels would
be more likely to respond to pacritinib was not supported
by our observations. However, since no patient had an
objective response to treatment this hypothesis cannot be
evaluated.
The phase III CORRECT trial of regorafenib
versus placebo found a small survival benefit in favor of
regorafenib. Despite the modest difference, it supported
a role for small-molecule multikinase inhibitors in the
treatment of refractory colorectal cancer. Our median PFS
expectation for pacritinib was deliberately set based on these
results and pacritinib did not meet this endpoint. Further
study of pacritinib as a single agent is not warranted based
on our study, however; novel combinations with drugs
targeting other molecular pathways could be explored.
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